Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pharmos (PARS) -- Ignore unavailable to you. Want to Upgrade?

To: arnie h who wrote (932)	10/23/1999 12:02:00 PM
From: Shadow	Read Replies (1) \| Respond to of 1386

Re:delisting NASDQ looks at other issues aside from stock price alone. A company which ships product and has a revenue stream will recieve more leeway than one which doesn't. A company with questionable books may be delisted even if they do a reverse split and bring their price over a dollar. A stock can't stay under $1 forever and expect to remain listed, but I don't think PARS shareholder need to start worrying yet. One thing that does concern me is year end tax loss selling. At its current level tax loss selling could easily put us way under a dollar.